NDA 220152 · Vanda Pharms INC
Nereus
Tradipitant · Oral
NovelCDER novel approval, Dec 30, 2025: To treat vomiting associated with motion
Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Dec 30, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
16
9 Phase 3, 1 recruiting
FAERS reports
2
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 1, 2026.
NEREUS is indicated for the prevention of vomiting induced by motion in adults. NEREUS is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for the prevention of vomiting induced by motion in adults. ( 1 )
Mechanism: Tradipitant is a selective, high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Tradipitant does not have affinity for NK2 and NK3 receptors, serotonin (5-HT3), dopamine (D2), cholinergic, or histamine (H1) receptors. Tradipitant has been shown in animal models to inhibit drug induced emesis. Human Positron Emission Tomography (PET) studies with tradipitant have shown that tradipitant crosses the blood brain barrier and occupies brain NK-1 receptors. The exact mechanism by which tradipitant exerts its therapeutic effect is not fully established.
Therapeutic areas: Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- NEREUS · TRADIPITANT 85MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tradipitant" as an intervention, any sponsor and status, largest first.
- Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT04028492 · 979 participants · Start Aug 20, 2019 · Primary completion Feb 21, 2025
Drug: Tradipitant; Placebo and 1 more · For: Idiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesis
Sites: Birmingham, Alabama; Peoria, Arizona; Little Rock, Arkansas · 36 sites in all
- Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessPivotal-lookingActive, not recruiting
Vanda PharmaceuticalsIndustry
NCT06138613 · 705 participants · Start Feb 27, 2023 · Primary completion Sep 30, 2027
Drug: Tradipitant · For: Motion Sickness
Sites: Santa Monica, California
- Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)Pivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT03568331 · 375 participants · Start Jul 9, 2018 · Primary completion Dec 27, 2019
Drug: Tradipitant; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Tempe, Arizona; Encino, California · 70 sites in all
- Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT04327661 · 366 participants · Start Nov 15, 2021 · Primary completion Apr 1, 2023
Drug: Tradipitant; Placebo · For: Motion Sickness
Sites: San Diego, California; Santa Monica, California; Fort Myers, Florida · 7 sites in all
- Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT05903924 · 316 participants · Start Sep 9, 2023 · Primary completion Apr 6, 2024
Drug: Tradipitant; Placebo · For: Motion Sickness
Sites: San Diego, California; San Jose, California; Santa Monica, California · 5 sites in all
- ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 InfectionPivotal-lookingEnrolling by invitation
Vanda PharmaceuticalsIndustry
NCT04326426 · 300 participants (planned) · Start Apr 13, 2020 · Primary completion Aug 1, 2020
Drug: Tradipitant; Placebo · For: Coronavirus Infection
Sites: New York, New York
- A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UsePivotal-lookingRecruiting
Vanda PharmaceuticalsIndustry
NCT07446439 · 280 participants (planned) · Start Mar 27, 2026 · Primary completion Dec 1, 2026
Drug: Tradipitant; Placebo · For: Nausea and Vomiting; Obesity
Sites: Los Angeles, California; San Diego, California; San Jose, California · 10 sites in all
- Tradipitant in Treatment-resistant Pruritus Associated With Atopic DermatitisPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT02651714 · 168 participants · Start Jan 19, 2016 · Primary completion Aug 4, 2017
Drug: Tradipitant; Placebo · For: Atopic Dermatitis
Sites: Encinitas, California; Encino, California; Lomita, California · 28 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- renal tubular necrosis2
- blood creatinine increased1
- protein total increased1
- sepsis1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The Efficacy of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Phase 3 Randomized Placebo-Controlled Clinical Trial.
Carlin JL, Polymeropoulos C, Camilleri M, et al. · Clin Gastroenterol Hepatol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Evaluation of tradipitant, a selective NK1 antagonist, on response to oxycodone in humans.
Coe MA, Lofwall MR, Vessels V, et al. · Psychopharmacology (Berl) 2021 · Randomized Controlled Trial
- Clinical trial: a single-centre, randomised, controlled trial of tradipitant on satiation, gastric functions, and serum drug levels in healthy volunteers.
Khanna L, Zheng T, Atieh J, et al. · Aliment Pharmacol Ther 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial.
Carlin JL, Lieberman VR, Dahal A, et al. · Gastroenterology 2021 · Clinical Trial, Phase II, Multicenter Study
- Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients'.
Smieszek SP, Przychodzen BP, Polymeropoulos VM, et al. · Cytokine 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Neurokinin-1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial.
Welsh SE, Xiao C, Kaden AR, et al. · J Eur Acad Dermatol Venereol 2021 · Letter, Randomized Controlled Trial
Sponsor: Vanda Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.